Cytological diagnosis of a rare synchronous non‐small cell lung cancer metastatic to the thyroid gland

Bizzarro, Tommaso; Bernardi, Livia; Buda, Raffaella; Rossi, Giulio

doi:10.1111/cyt.12832

Cited by 2 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EGFR and EML4-ALK gene mutations are associated with thyroid metastasis of lung cancer, but the exact mechanism is not clear [ 33 ]. The combined use of morphological fine-needle aspiration biopsy (FNAB) features with immunohistochemistry (IHC) analysis of adequate cell content on smeared specimens, as well as on cell-block material, is a feasible and reliable method to achieve a definitive diagnosis of metastatic nonsmall cell lung cancer to the thyroid gland [ 35 ]. In terms of prognosis, the prognosis of patients with adenocarcinoma was significantly better than that of patients with squamous cell carcinoma or other histological types [ 36 ].…”

Section: The Primary Tumormentioning

confidence: 99%

Metastases to the Thyroid Gland: What Can We Do?

Tang

Wang

2022

Cancers

View full text Add to dashboard Cite

Metastases to the thyroid gland arise from other malignant tumors such as renal cell carcinoma, colorectal cancer, lung cancer, and breast cancer. In clinical practice, the incidence is low, and the symptoms are not specific, so it is often missed and misdiagnosed. It is finally diagnosed via the comprehensive application of many diagnostic methods, such as ultrasound, fine-needle aspiration biopsy, and immunohistochemistry analysis. Surgery-based comprehensive treatment is often adopted, but because it is usually in the late stage of the primary tumor, the prognosis is poor. In order to better understand the related characteristics of thyroid metastatic cancer and then improve the clinical diagnosis and treatment and the prognosis of patients, in this paper, we systematically summarize the research status of thyroid metastatic cancer.

show abstract

Section: The Primary Tumormentioning

confidence: 99%

Metastases to the Thyroid Gland: What Can We Do?

Tang

Wang

2022

Cancers

View full text Add to dashboard Cite

show abstract

“…The commonly used methods for the diagnosis and prognosis of cancers are (1) imaging examination: including X-ray, CT, magnetic resonance imaging (MRI), ultrasound, endoscopy, glucose metabolism technology and positron emission tomography (PET), radionuclide imaging examination and other imaging methods [ 3 , 4 , 5 ]; (2) molecular marker examination: including detection of tumor markers such as carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), and various carbohydrate antigens (such as CA125 and CA19) and some tumor-related biochemical indicators such as acid phosphatase (ACP), estrogen receptor (ER), and progesterone receptor (PR) in serum urine of patients [ 4 , 6 , 7 , 8 , 9 ]; (3) pathological examination where the abnormal tissue samples are collected for pathological examination by techniques such as immunohistochemistry (IHC), HE staining, and fluorescence in situ hybridization (FISH) [ 10 , 11 ]; (4) detection of circulating tumor cells (CTC), such as detection of tumor cells in peripheral blood, which can be used to monitor and predict the prognosis of tumor metastasis [ 12 , 13 ]; (5) body fluid cytological diagnosis, including detection of tumor cells by sputum, urine and other liquids or by means of puncture [ 14 , 15 ]; and (6) other examinations: including digital rectal examination (DRE), fecal occult blood test (FOBT), and other diagnostic methods [ 16 , 17 ].…”

Section: Introductionmentioning

confidence: 99%

Overview of MicroRNAs as Diagnostic and Prognostic Biomarkers for High-Incidence Cancers in 2021

Sun

Zhao

Wang

et al. 2022

IJMS

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are small non-coding RNAs (ncRNAs) about 22 nucleotides in size, which play an important role in gene regulation and are involved in almost all major cellular physiological processes. In recent years, the abnormal expression of miRNAs has been shown to be associated with human diseases including cancer. In the past ten years, the link between miRNAs and various cancers has been extensively studied, and the abnormal expression of miRNAs has been reported in various malignant tumors, such as lung cancer, gastric cancer, colorectal cancer, liver cancer, breast cancer, and prostate cancer. Due to the high malignancy grade of these cancers, it is more necessary to develop the related diagnostic and prognostic methods. According to the study of miRNAs, many potential cancer biomarkers have been proposed for the diagnosis and prognosis of diseases, especially cancer, thus providing a new theoretical basis and perspective for cancer screening. The use of miRNAs as biomarkers for diagnosis or prognosis of cancer has the advantages of being less invasive to patients, with better accuracy and lower price. In view of the important clinical significance of miRNAs in human cancer research, this article reviewed the research status of miRNAs in the above-mentioned cancers in 2021, especially in terms of diagnosis and prognosis, and provided some new perspectives and theoretical basis for the diagnosis and treatment of cancers.

show abstract

Cytological diagnosis of a rare synchronous non‐small cell lung cancer metastatic to the thyroid gland

Cited by 2 publications

References 9 publications

Metastases to the Thyroid Gland: What Can We Do?

Metastases to the Thyroid Gland: What Can We Do?

Overview of MicroRNAs as Diagnostic and Prognostic Biomarkers for High-Incidence Cancers in 2021

Contact Info

Product

Resources

About